Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: An analysis of Eastern Cooperative Oncology Group trials

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1410-1416

  Argiris, Athanassios ^a   Li, S ^b   Ghebremichael, M ^c   Egloff, A M ^d   Wang, L ^d   Forastiere, A A ^e   Burtness, B ^f   Mehra, R ^f  

^a University of Texas Health Science Center   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

Author keywords

Head and neck cancer; Human papillomavirus

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; PACLITAXEL; PROTEIN P16; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL DIFFERENTIATION; DRUG RESPONSE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WART VIRUS; WEIGHT REDUCTION; ALPHAPAPILLOMAVIRUS; HEAD AND NECK TUMOR; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECURRENCE;

EID: 84903748627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu167     Document Type: Article

References (27)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97: 72-81.
2. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
3. Stransky N, Egloff AM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
4. Jordan RC, Lingen MW, Perez-Ordonez B et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 2012; 36: 945-954.
5. Lingen MW, Xiao W, Schmitt A et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 2013; 49: 1-8.
6. Weinberger PM, Yu Z, Kountourakis P et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg 2009; 141: 382-389.
7. Gillison ML, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
8. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
9. Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14.
10. Posner MR, Lorch JH, Goloubeva O et al. Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. In ASCO. J Clin Oncol 2010; A5525.
11. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
12. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636.
13. Gibson MK, Li Y, Murphy B et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
14. Argiris A, Buchanan A, Brockstein B et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4504-4513.
15. Argiris A, Heron DE, Smith RP et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010; 28: 5294-5300.
16. Wheeler S, Siwak DR, Chai R et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 2012; 18: 2278-2289.
17. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101: 2222-2229.
18. Zuo Z, Keck MK, Khattri A et al. Multimodality determination of HPV status in head and neck cancers (HNC) and development of an HPV signature. J Clin Oncol 2013; 31 (suppl): abstr 6008.
19. Chung CH, Zhang Q, Kong C et al. p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). J Clin Oncol 2013; 31 (suppl): abstr 6007.
20. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
21. O'Sullivan B, Huang SH, Siu LL et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013; 31: 543-550.
22. Vermorken JB, Stohlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamouscell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14: 697-710.
23. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
24. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
25. Psyrri A, Licitra L, De Blas B et al. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III EXTREME trial. In ESMO 2012 (Abstr 10180).
26. Vermorken JB, Psyrri A, Mesia R et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014; 25: 801-807.
27. Seiwert T. Accurate HPV testing: a requirement for precision medicine for head and neck cancer. Ann Oncol 2013; 24: 2711-2713.